Diagnoly secures €5.5M in seed funding to enhance AI-driven prenatal screening technologies aimed at reducing undetected fetal abnormalities.

Information on the Target

Diagnoly is an innovative DeepTech firm focused on reinventing prenatal screening through advanced artificial intelligence technology. Established in late 2018, the company's mission is to enhance the reliability of fetal ultrasound examinations, addressing a critical gap in the detection of fetal abnormalities, where studies indicate that around 50% go unnoticed until birth. The founding team, composed of experts in applied mathematics and obstetrics, aims to develop a solution that significantly increases the accuracy of prenatal screenings.

The idea for Diagnoly was sparked by the personal experiences of co-founder Ivan Voznyuk during his wife's pregnancy. Following discussions with renowned obstetrician-gynecologist Dr. Edwin Quarello and the addition of computer vision engineer Camille Dupont, the company began to take shape. Diagnoly's focus is to advance fetal-maternal medicine and safeguard women's health through more precise prenatal diagnostics, specifically targeting cardiac and cerebral conditions.

Industry Overview in France

The prenatal screening industry in France is witnessing substantial growth, driven by the increasing adoption of sophisticated diagnostic techniques and advancements in medical technology. France's robust healthcare system prioritizes maternal and child health,